179 related articles for article (PubMed ID: 29538736)
1. Aspergillus terreus: Novel lessons learned on amphotericin B resistance.
Posch W; Blatzer M; Wilflingseder D; Lass-Flörl C
Med Mycol; 2018 Apr; 56(suppl_1):73-82. PubMed ID: 29538736
[TBL] [Abstract][Full Text] [Related]
2. Antifungal resistance in Aspergillus terreus: A current scenario.
Vahedi Shahandashti R; Lass-Flörl C
Fungal Genet Biol; 2019 Oct; 131():103247. PubMed ID: 31247322
[TBL] [Abstract][Full Text] [Related]
3. Blocking Hsp70 enhances the efficiency of amphotericin B treatment against resistant Aspergillus terreus strains.
Blatzer M; Blum G; Jukic E; Posch W; Gruber P; Nagl M; Binder U; Maurer E; Sarg B; Lindner H; Lass-Flörl C; Wilflingseder D
Antimicrob Agents Chemother; 2015 Jul; 59(7):3778-88. PubMed ID: 25870060
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B Resistance in Aspergillus terreus Is Overpowered by Coapplication of Pro-oxidants.
Blatzer M; Jukic E; Posch W; Schöpf B; Binder U; Steger M; Blum G; Hackl H; Gnaiger E; Lass-Flörl C; Wilflingseder D
Antioxid Redox Signal; 2015 Dec; 23(18):1424-38. PubMed ID: 26054424
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo role of heat shock protein 90 in Amphotericin B resistance of Aspergillus terreus.
Blum G; Kainzner B; Grif K; Dietrich H; Zeiger B; Sonnweber T; Lass-Flörl C
Clin Microbiol Infect; 2013 Jan; 19(1):50-55. PubMed ID: 22515428
[TBL] [Abstract][Full Text] [Related]
6. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
7. Potential basis for amphotericin B resistance in Aspergillus terreus.
Blum G; Perkhofer S; Haas H; Schrettl M; Würzner R; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2008 Apr; 52(4):1553-5. PubMed ID: 18268082
[TBL] [Abstract][Full Text] [Related]
8. New insight into amphotericin B resistance in Aspergillus terreus.
Blum G; Hörtnagl C; Jukic E; Erbeznik T; Pümpel T; Dietrich H; Nagl M; Speth C; Rambach G; Lass-Flörl C
Antimicrob Agents Chemother; 2013 Apr; 57(4):1583-8. PubMed ID: 23318794
[TBL] [Abstract][Full Text] [Related]
9. Oxidative Stress Response Tips the Balance in Aspergillus terreus Amphotericin B Resistance.
Jukic E; Blatzer M; Posch W; Steger M; Binder U; Lass-Flörl C; Wilflingseder D
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739793
[TBL] [Abstract][Full Text] [Related]
10. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
11.
Vahedi-Shahandashti R; Dietl AM; Binder U; Nagl M; Würzner R; Lass-Flörl C
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0227421. PubMed ID: 35254091
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
13. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species.
Fakhim H; Badali H; Dannaoui E; Nasirian M; Jahangiri F; Raei M; Vaseghi N; Ahmadikia K; Vaezi A
J Mycol Med; 2022 Nov; 32(4):101310. PubMed ID: 35907396
[TBL] [Abstract][Full Text] [Related]
14. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
[TBL] [Abstract][Full Text] [Related]
16. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
17. Luliconazole, an alternative antifungal agent against Aspergillus terreus.
Zargaran M; Taghipour S; Kiasat N; Aboualigalehdari E; Rezaei-Matehkolaei A; Zarei Mahmoudabadi A; Shamsizadeh F
J Mycol Med; 2017 Sep; 27(3):351-356. PubMed ID: 28483449
[TBL] [Abstract][Full Text] [Related]
18. Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility.
Speth C; Blum G; Hagleitner M; Hörtnagl C; Pfaller K; Posch B; Ott HW; Würzner R; Lass-Flörl C; Rambach G
Med Microbiol Immunol; 2013 Oct; 202(5):379-89. PubMed ID: 23722593
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of amphotericin B and micafungin combination against clinical isolates of Aspergillus species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Chemother; 2011 Apr; 23(2):102-6. PubMed ID: 21571627
[TBL] [Abstract][Full Text] [Related]
20. In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex.
Vaezi A; Fakhim H; Arastehfar A; Shokohi T; Hedayati MT; Khodavaisy S; Rezaei-Matehkolaei A; Badiee P; Hagen F; Lass-Flörl C; Dannaoui E; Meis JF; Badali H
Mycoses; 2018 Feb; 61(2):134-142. PubMed ID: 29064123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
